Literature DB >> 32582957

Multimodal Analgesia and Discharge Opioid Requirements in Burn Patients.

Michael Wright1, Jin A Lee1.   

Abstract

Analgesia in burn patients is challenging given the complexity of burn pain and prolonged need beyond hospital admission. Given the risks of opioids, the impact of multimodal analgesia postdischarge needs to be further elucidated in this population. This retrospective, single-center cohort study evaluated adult burn patients who were consecutively admitted to the burn service with at least 10% total body surface area burned and subsequently followed in the burn clinic between February 2015 and September 2018. Subjects were separated into two cohorts based on discharge pain regimens: multimodal and nonmultimodal. The primary outcome was the change in opioid requirements (measured in oral morphine equivalents) between discharge and first follow-up interval. Secondary outcomes included the classes of multimodal agents utilized and a comparison of opioid requirements between the last 24 hours of admission and discharge. A total of 152 patients were included for analysis, 76 in the multimodal cohort and 76 in the nonmultimodal cohort. The multimodal cohort was noted to have increased total body surface area burned and prolonged number of days spent in the intensive care unit at baseline; however, the multimodal cohort exhibited a more significant decrease in opioid requirements from discharge to first follow-up interval when compared with the nonmultimodal cohort (106.6 vs 75.4 mg, P = .039). Published by Oxford University Press on behalf of the American Burn Association 2020.

Entities:  

Year:  2020        PMID: 32582957      PMCID: PMC7510840          DOI: 10.1093/jbcr/iraa088

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  8 in total

1.  An evaluation of discharge opioid prescribing practices in a burn population.

Authors:  Lucy Wibbenmeyer; Kate Oltrogge; Karen Kluesner; M Bridget Zimmerman; Patrick G Kealey
Journal:  J Burn Care Res       Date:  2015 Mar-Apr       Impact factor: 1.845

Review 2.  Efficacy and feasibility of opioids for burn analgesia: An evidence-based qualitative review of randomized controlled trials.

Authors:  Chao Yang; Xiao-Min Xu; Guang-Zhao He
Journal:  Burns       Date:  2017-11-21       Impact factor: 2.744

3.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.

Authors:  Deborah Dowell; Tamara M Haegerich; Roger Chou
Journal:  MMWR Recomm Rep       Date:  2016-03-18

4.  Multimodal Analgesia and Opioid Use in Critically Ill Trauma Patients.

Authors:  Kasey L Hamrick; Carl A Beyer; Jin A Lee; Christine S Cocanour; Jeremiah J Duby
Journal:  J Am Coll Surg       Date:  2019-02-21       Impact factor: 6.113

5.  Pregabalin in severe burn injury pain: a double-blind, randomised placebo-controlled trial.

Authors:  Paul Gray; Julie Kirby; Maree T Smith; Peter J Cabot; Bronwyn Williams; James Doecke; Tess Cramond
Journal:  Pain       Date:  2011-03-12       Impact factor: 6.961

Review 6.  Pain and the thermally injured patient-a review of current therapies.

Authors:  Helene Retrouvey; Shahriar Shahrokhi
Journal:  J Burn Care Res       Date:  2015 Mar-Apr       Impact factor: 1.845

7.  Gabapentin is ineffective as an analgesic adjunct in the immediate postburn period.

Authors:  Lucy Wibbenmeyer; Anas Eid; Junlin Liao; Jason Heard; Aaron Horsfield; Lee Kral; Pat Kealey; Richard Rosenquist
Journal:  J Burn Care Res       Date:  2014 Mar-Apr       Impact factor: 1.845

8.  Effect of gabapentin on morphine consumption and pain after surgical debridement of burn wounds: a double-blind randomized clinical trial study.

Authors:  Siamak Rimaz; Cyrus Emir Alavi; Abbas Sedighinejad; Mohammad Tolouie; Sharareh Kavoosi; Leila Koochakinejad
Journal:  Arch Trauma Res       Date:  2012-06-01
  8 in total
  1 in total

1.  Prescribing of Gabapentinoids with or without opioids after burn injury in the US, 2012-2018.

Authors:  Efstathia Polychronopoulou; Yong-Fang Kuo; Denise Wilkes; Mukaila A Raji
Journal:  Burns       Date:  2021-12-22       Impact factor: 2.744

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.